We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.71 | 2.24% | 32.34 | 31.61 | 32.60 | 32.34 | 31.93 | 32.21 | 48,814 | 21:14:42 |
From May 2019 to May 2024
By Colin Kellaher
ObsEva SA (OBSV) on Thursday said a phase 3 study of nolasiban missed its primary endpoint, and the biopharmaceutical company said it would end its in-vitro fertilization program for the drug.
ObsEva said its European confirmatory study of nolasiban in women undergoing embryo transfer following in-vitro fertilization didn't meet the primary endpoint of an increase in ongoing pregnancy rate at 10 weeks.
"We are extremely disappointed with these unexpected results," the Geneva-based company said, adding that it would explore potential repositioning of the product candidate.
ObsEva licensed nolasiban, an oral oxytocin receptor antagonist, from Merck KGaA (MRK.XE) and retains worldwide, exclusive commercial rights.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 07, 2019 06:53 ET (11:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
